Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?

Lancet Neurology

Volumn 6, Issue 4, 2007, Pages 373-378

  Kehoe, Patrick G ^a   Wilcock, Gordon K ^b  

^a Institute of Clinical Neurosciences   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IMIDAPRIL; INDAPAMIDE; NIFEDIPINE; NILVADIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; DEMENTIA; DRUG MECHANISM; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE;

EID: 33847791727     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70077-7     Document Type: Note

References (46)

1. Skoog I., and Gustafson D. Hypertension, hypertension-clustering factors and Alzheimer's disease. Neurol Res 25 (2003) 675-680
2. Papademetriou V. Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature. Geriatrics 60 (2005) 20-22
3. Dannenberg A., Garrison R., and Kannel W. Incidence of hypertension in the Framingham Study. Am J Public Health 78 (1988) 676-679
4. Trenkwalder P. Potential for antihypertensive treatment with an AT(1)-receptor blocker to reduce dementia in the elderly. J Hum Hypertens 16 suppl 3 (2002) S71-S75
5. Luchsinger J., and Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 6 (2004) 261-266
6. Love S. Contribution of cerebral amyloid angiopathy to Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 (2004) 1-4
7. *-Ala-based pentapeptide mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg Med Chem Lett 14 (2004) 239-243
8. Wong G., Manfra D., Poulet F., et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279 (2004) 12876-12882
9. Wilcock G., Black S., Howarth J., et al. A placebo-controlled, double-blind trial of the selective AB-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer's disease. Alzheimers Dement 1 (2005) 95
10. Nicoll J., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9 (2003) 448-452
11. Hanon O., Latour F., Seux M., Lenoir H., Forette F., and Rigaud A. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR). J Nutr Health Aging 9 (2005) 106-111
12. Chiu A., Herblin W., McCall D., et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 165 (1989) 196-203
13. Whitebread S., Mele M., Kamber B., and de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163 (1989) 284-291
14. Stanton A. Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4 (2003) 6-10
15. Reaux A., Iturrioz X., Vazeux G., et al. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochem Soc Trans 28 (2000) 435-440
16. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 63 (2003) 2185-2202
17. Forette F., Seux M., Staessen J., et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352 (1998) 1347-1351
18. Tzourio C., Anderson C., Chapman N., et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163 (2003) 1069-1075
19. Hanon O., and Forette F. Prevention of dementia: lessons from SYST-EUR and PROGRESS. J Neurol Sci 226 (2004) 71-74
20. Hanon O., Seux M., Lenoir H., Rigaud A., and Forette F. Prevention of dementia and cerebroprotection with antihypertensive drugs. Curr Hypertens Rep 6 (2004) 201-207
21. Khachaturian A., Zandi P., Lyketsos C., et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol 63 (2006) 686-692
22. Breitner J., Wyse B., Anthony J., et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 53 (1999) 321-331
23. Ohrui T., Matsui T., Yamaya M., et al. Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc 52 (2004) 649-650
24. Ohrui T., Tomita N., Sato-Nakagawa T., et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63 (2004) 1324-1325
25. Rozzini L., Chilovi B., Bertoletti E., et al. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry 21 (2006) 550-555
26. Jenkins T., and Chai S. Effect of angiotensin converting enzyme inhibitors on memory. Neurobiol Learn Mem 87 (2007) 218-224
27. Barnes J., Barnes N., Costall B., et al. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol 19 suppl 6 (1992) S63-S71
28. Kehoe P. The renin-angiotensin-aldosterone system and Alzheimer s disease?. J Renin Angiotensin Aldosterone Syst 4 (2003) 80-93
29. Savaskan E. The role of the brain renin-angiotensin system in neurodegenerative disorders. Curr Alzheimer Res 2 (2005) 29-35
30. Carson J., and Turner A. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J Neurochem 81 (2002) 1-8
31. Hemming M., and Selkoe D. Amyloid beta -protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280 (2005) 37644-37650
32. Hu J., Igarashi A., Kamata M., and Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276 (2001) 47863-47868
33. Oba R., Igarashi A., Kamata M., Nagata K., Takano S., and Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 21 (2005) 733-740
34. Lehmann D., Cortina-Borja M., Warden D., et al. Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol 162 (2005) 305-317
35. Rigat B., Hubert C., Alhenc-Gelas F., Cambien F., Corvol P., and Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
36. Kehoe P., Russ C., McIlory S., et al. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat Genet 21 (1999) 71-72
37. Kehoe P., Katzov H., Feuk L., et al. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum Mol Genet 12 (2003) 859-867
38. Meng Y., Baldwin C., Bowirrat A., et al. Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. Am J Hum Genet 78 (2006) 871-877
39. Lendon C., Thaker U., Harris J., et al. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett 328 (2002) 314-318
40. Eckman E., Adams S., Troendle F., et al. Regulation of steady-state beta -amyloid levels in the brain by neprilysin and endothelin-converting enzyme, but not angiotensin-converting enzyme. J Biol Chem 281 (2006) 30471-30478
41. Klein. Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement 2 (2006) 43-55
42. Forette F., Seux M., Staessen J., et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 162 (2002) 2046-2052
43. Saido T., and Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 54 (2006) 235-253
44. Miners J., Van Helmond Z., Chalmers K., Wilcock G., Love S., and Kehoe P. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65 (2006) 1012-1021
45. Fogari R., Preti P., Mugellini A., et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens 15 4 part 2 (2002) 36A
46. Haulica I., Bild W., and Serban D. Angiotensin peptides and their pleiotropic actions. J Renin Angiotensin Aldosterone Syst 6 (2005) 121-131